Table 3.

Risk of non-persistence of biosimilar use versus originator use in etanercept-initiating patients, by pathology

Pathology	Reference events	Biosimilars events	Raw HR	P value	IPTW aHR	P value
Rheumatoid arthritis	48% (2731/5640)	42% (2380/5625)	0.84 (0.78 to 0.90)	<0.001	0.85 (0.78 to 0.93)	<0.001
Ankylosing spondylitis	55% (2977/5447)	49% (2078/4255)	0.86 (0.80 to 0.92)	<0.001	0.88 (0.80 to 0.96)	<0.001
Psoriasic arthritis	53% (484/905)	49% (320/651)	0.86 (0.72 to 1.03)	0.033	0.82 (0.65 to 1.03)	0.031
Psoriasis	57% (773/1362)	51% (286/557)	0.90 (0.76 to 1.07)	0.123	0.80 (0.65 to 1.00)	0.011

HRs are presented in point estimates (CI); bold font denotes significant differences. Bonferroni-corrected p value=0.0125.

IPTW computed through a multivariable logistic regression.

aHR, adjusted HR; IPTW, inverse probability of treatment weighting.